Siwu Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

Siwu Powder Veterinary Grade API is a purified active pharmaceutical ingredient powder supplied as a multi-route input for tablets, injections, capsules, powders, granules, premixes, and solutions. The model designation covers a single active substance with application-specific release criteria rather than separate chemical entities. Production is performed under current good manufacturing practice aligned with 21 CFR 211 and VICH GL18; individual batches are released after assay, related-substance, water-content, residual-solvent, elemental-impurity, and microbial testing. Lot-specific certificates of analysis remain the controlling documents. The powder is not marketed as a sterile substance; therefore injectable preparations require terminal sterilisation or aseptic filtration at the dosage-form manufacturing site. Where all finished formulation possibilities have not been individually qualified, published data for these specific configurations is limited and should be addressed through product-specific validation.

Release Specifications and the Pharmacopoeial Test Framework

For solid oral applications, particle-size distribution is measured by laser diffraction according to USP <429>, with representative acceptance of D90 ≤ 150 µm and D50 between 30 µm and 80 µm. Bulk density and tapped density are determined by Ph. Eur. 2.9.34; milled batches commonly show values from 0.42 g/cm³ to 0.58 g/cm³, with a Hausner ratio not exceeding 1.35 when direct compression is intended. Water content is controlled by Karl Fischer titration using USP <921> Method Ia and is commonly limited to ≤ 0.5%. Residual solvents follow VICH GL18; Class 1 solvents are not detected and Class 2 solvents are controlled at the concentration limits of Ph. Eur. 5.4. Elemental impurities are assessed by ICP-MS according to ICH Q3D and USP <233>; cadmium, lead, arsenic, and mercury are limited to the permitted daily exposure for the labelled route. Non-sterile microbial limits follow USP <61> and USP <62>, with TAMC ≤ 10³ CFU/g, TYMC ≤ 10² CFU/g, and absence of Escherichia coli, Salmonella, and Staphylococcus aureus. Assay is performed by HPLC using USP <621>; release acceptance is normally 98.0% to 102.0% on the dried basis.

Table 1 summarises the release matrix for the main routes.

Can a Single Lot Be Distributed Across Solid Oral and Liquid Dosage Forms?

A single lot can be assigned to multiple routes only if the lot meets the tightest specification for every intended route. A batch released solely for tablet or capsule use is not automatically acceptable for injectable solution manufacture because of the additional bacterial endotoxin, subvisible particulate, and sterile-input requirements. When a lot is intended for both powder/granule and parenteral use, the injectable particle-size and endotoxin tests must be included on the CoA. The finished dosage manufacturer retains responsibility for terminal sterilisation, aseptic processing, or sterile filtration and for demonstrating that the selected vehicle does not alter the active substance. pH-solubility and co-solvent compatibility data are formulation-specific. Published data for this specific API in all possible licensed solutions is limited, so shake-flask solubility screening under the proposed pH, ionic strength, and temperature is recommended before scale-up.

On production-scale solid oral lines, the powder is introduced into a bin blender or V-blender with excipients. Dry direct compression is generally feasible when the API D90 remains below 125 µm and the excipient-to-API bulk-density difference is less than 0.25 g/cm³. At higher D90 values, wet granulation is preferred to avoid segregation. In high-shear granulators with impeller speed from 200 rpm to 400 rpm and wet massing time of 2 min to 4 min, the powder is typically granulated with povidone or pregelatinised starch; drying in a fluid-bed dryer at inlet air temperature 55 °C to 65 °C is continued until loss on drying reaches 1.5% to 2.5%. These operating windows are general for similar milled actives and should be confirmed by factorial trials on the target equipment.

During capsule filling on an automatic dosator or tamping-pin machine, fill weight variation is reduced when the Hausner ratio is below 1.35 and the D90 is ≤ 180 µm; otherwise wet granulation or slugging is usually applied. Fill weight uniformity is assessed per USP <905>; dissolution of the finished solid form is tested by USP <711>. Tablet hardness and friability are tested by USP <1217> and USP <1216> respectively. Precompression force from 5 kN to 10 kN and main compression force from 10 kN to 25 kN are common starting values for rotary tablet presses processing wet granulated material.

For Injections and Solutions, the Powder Must Meet Tighter Purity Limits

For solution and injectable preparation, the API should be checked for particulate matter in the pre-filtration solution using USP <788> Method 1. Terminal sterilisation or aseptic filtration through a 0.22 µm PVDF or PES membrane is required at the finished-product facility. Filter compatibility and active-substance adsorption should be tested with the actual membrane polymer and contact time. Endotoxin limits are calculated from the maximum bolus dose and route using USP <85>. If the product is intended for subcutaneous, intramuscular, or intra-mammary administration, pH adjustment into the range 4.0 to 8.0 is usually evaluated, although the approved range is formulation-specific. Forced degradation solutions at 40 °C and 75% RH for up to 6 months, or photostability testing under ICH Q1B, may be used to demonstrate solution stability. Dissolved oxygen can accelerate oxidative degradation; nitrogen sparging to ≤ 1 mg/L dissolved oxygen is often used for oxygen-sensitive APIs. The powder is not supplied as sterile; injectable-grade requirements therefore remain a shared responsibility between the API manufacturer and the finished-product manufacturer.

For solutions, the API is dissolved in purified water or a co-solvent system before filtration. Dissolution time and saturated solubility are measured by the shake-flask method at 25 °C and 37 °C; if saturation concentration is below the target finished concentration, pH adjustment or co-solvents may be required. Aqueous solubility is reported in the batch CoA only when ordered as solution-grade. Published data for this specific API across all co-solvent ratios is limited; the formulator must establish the maximum stable concentration in the final container.

When the API Is Processed into Premixes and Granulated Feed Additives

Feed premix and granule production requires an initial geometric pre-blend before low-shear mixing. The API is usually dispersed into a carrier such as lactose monohydrate or corncob at a ratio of at least 1:10 drug to carrier; the pre-blend is then added to the mixer and diluted to the final concentration. Blend uniformity is assessed by sampling not fewer than 10 locations and quantified by USP <905> or an equivalent finished-product scheme, with individual samples between 90.0% and 110.0% of label claim and an RSD of ≤ 5.0%. For roller compaction of dry granules, roller pressure from 40 kN to 80 kN and screen milling through 0.8 mm to 1.25 mm mesh are common starting points for similar milled actives. Moisture uptake in premix areas should be controlled; extended exposure above 60% RH can reduce flow and increase sticking. If the premix contains mineral premixes or choline chloride, the API should be evaluated for adsorption and degradation; published data for these specific combinations is limited.

Compared with unprocessed bulk actives, Siwu Powder is released under a defined particle-size distribution and microbial-control scheme. The main differences are that tablet, capsule, and injectable grades are supported by the same documentation set; residual solvent and elemental impurity data are provided; and the powder is tested for microbial limits as a non-sterile ingredient. The product is not sterile and is not intended as a ready-to-inject solution. Unlike some single-route veterinary powders, the multi-route designation requires tighter moisture and particle-size control because a batch may later be assigned to an injectable or solution line. This does not eliminate downstream validation; it reduces incoming raw material variability when the same active substance is qualified for multiple dosage forms.

Storage is specified at 25 °C or below in a light-resistant container. The powder is packaged in double low-density polyethylene liners inside an aluminium foil bag with desiccant to maintain water content. Moisture protection is required because the powder can adsorb water above 60% RH. After opening, the container should be resealed under nitrogen and the water content retested if the open period exceeds 30 days. Compatibility with common excipients should be screened by binary mixtures stored at 40 °C and 75% RH for 4 weeks; analysis by HPLC for new related substances is advised. Avoid combination with strong oxidising agents and transition-metal salts unless forced degradation data support the formulation. The powder should not be exposed to open alkaline solutions above pH 8.0 for extended periods without product-specific stability verification.

Method transfer to incoming quality-control laboratories should include verification of assay and related substances by HPLC with column, mobile-phase, and detection wavelength as specified in the technical dossier. System suitability criteria for resolution and tailing factor should follow USP <621>; if no pharmacopoeial monograph exists, the API manufacturer supplies a validated in-house method. The receiving laboratory should revalidate the method for the specific finished matrix before use. Aqueous solubility and particle-size methods should be rechecked against reference batches to ensure inter-laboratory comparability.